While standard seasonal flu shots primarily target rapidly evolving strains and offer limited cross-protection, emerging evidence suggests that certain formulations and adjuvants may provide some baseline immune priming or cross-reactivity against potential pandemic strains.
The evidence we hold leans evenly split
official record 3x · fact-check 2x · hedged 1x · crowd & reference 1x